ARTICLE | Clinical News

Asfotase alfa: Additional Phase II data

October 11, 2010 7:00 AM UTC

Preliminary 6-month data from an open-label, historical cohort-controlled, North American Phase II trial in 13 patients ages 5-12 showed that thrice-weekly 2 or 3 mg/kg subcutaneous ENB-0040 produced skeletal radiographic improvement of rickets in all patients as assessed by investigators. Additionally, ENB-0040 improved 6-minute walk distance by an average of 125 m from baseline, and ameliorated pain in 6 of 7 patients experiencing baseline pain at 6 months. Data were presented at the European Society for Pediatric Endocrinology meeting in Prague. ...